<DOC>
	<DOCNO>NCT02535416</DOCNO>
	<brief_summary>Single dose ARC-520 evaluate vary infusion rate slow bolus push .</brief_summary>
	<brief_title>A Study ARC-520 Varying Infusion Rates Normal Adult Volunteers</brief_title>
	<detailed_description>This single-center , open-label , sequential cohort , single-dose study ARC-520 administer intravenously healthy adult volunteer . Eligible subject receive single intravenous injection ARC-520 . Up 8 cohort ( total approximately 40 subject ) may enrol . ARC-520 ( 4.0 mg/kg ) administer increase infusion rate bolus push cohort 5 . In addition dose level 5.0 mg/kg 6.0 mg/kg evaluate infusion rate 0.9 mL/min . For subject duration study clinic visit approximately 6 week ; maximum study duration approximately 17 week include follow-up telephone call day 30 , 60 90 . Participants undergo follow evaluation regular interval : medical history , physical examination , bee venom allergy blood test , vital sign measurement , weight , adverse event monitoring , ECGs , telemetry , pregnancy test ( female ) , concurrent medication , blood sample collection hematology , coagulation , chemistry , pharmacokinetics , pharmacodynamics , drug screen , urinalysis .</detailed_description>
	<criteria>Male female , 1855 year age , inclusive Able provide write informed consent BMI 19.0 35.0 kg/m2 , inclusive 12lead ECG Screening predose clinically significant abnormality Highly effective , double barrier contraception ( male female partner ) study 3 month follow dose ARC520 Willing able comply study assessment Suitable venous access blood sample Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) creatinine level normal range No abnormal find clinical relevance Pregnant/lactating Acute sign hepatitis/other infection within 4 week Screening Concurrent use anticoagulant , corticosteroid , immunomodulators , immunosuppressant . Use prescription medication within 14 day prior study treatment Depot injection/implant birth control within 3 month study treatment Known diagnosis diabetes mellitus History autoimmune disease especially autoimmune hepatitis . Human immunodeficiency virus ( HIV ) infection Seropositive hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Uncontrolled hypertension : blood pressure ( BP ) &gt; 150/100 mmHg History cardiac rhythm disturbance Family history congenital long QT syndrome , Brugada syndrome unexplained sudden cardiac death . Currently use medication know prolong correct QT interval ( QTc ) . Symptomatic heart failure ( per New York Heart Association guideline ) Unstable angina , myocardial infarction , severe cardiovascular disease , transient ischemic attack ( TIA ) cerebrovascular accident ( CVA ) within past 6 month History malignancy within last 5 year except adequately treat basal cell carcinoma , squamous cell skin cancer , superficial bladder tumor , situ cervical cancer Major surgery within 3 month Screening History alcohol and/or drug abuse &lt; 12 month Screening Regular use alcohol within 6 month Screening Evidence systemic acute inflammation , sepsis hemolysis . Clinically significant psychiatric disorder Use recreational drug within 3 month Screening drug , cocaine , phencyclidine ( PCP ) , methamphetamine , within 1 year Screening Positive urine drug screen History allergy hypersensitivity reaction bee venom Positive reaction bee venom Immunoglobulin E [ IgE ] test Use investigational agent device within 30 day study dose current participation investigational study . Clinically significant history/presence gastrointestinal pathology , unresolved gastrointestinal symptom , liver kidney disease Cholangitis , cholecystitis , cholestasis , duct obstruction Clinically significant history/presence neurological , endocrine , cardiovascular , pulmonary , hematological , immunologic , psychiatric , metabolic uncontrolled systemic disease Blood donation blood loss ( 500 mL ) within 30 day prior study treatment History fever within 2 week Screening . Excessive exercise/physical activity within 7 day Screening enrollment plan study . History coagulopathy , stroke within six ( 6 ) month baseline , and/or concurrent anticoagulant medication ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>